Advertisement

Reactions Weekly

, Volume 1636, Issue 1, pp 153–153 | Cite as

Gemcitabine

Digestive bleeding: case report
Case report
  • 22 Downloads
Author Information

An event is serious (FDA MedWatch definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * requires intervention to prevent permanent impairment or damage

In a retrospective study, a patient [age and sex not stated] was described, who developed digestive bleeding during treatment with gemcitabine [route not stated]. The patient with non-resected pancreatic adenocarcinoma received treatment with 50 mg/m2 gemcitabine twice daily. Subsequently, the patient experienced severe digestive bleeding [duration of treatment to reaction onset and outcome not stated]

Author comment: "All patients experienced G1 to G2 acute toxicity except one patient who presented with severe digestive bleeding potentially linked to the treatment."

Reference

  1. Lauffer D, et al. Non-resected and R1 resected pancreatic adenocarcinoma: Feasibility and patients' outcome after radio-chemotherapy with high dose external radiotherapy (RT). Strahlentherapie und Onkologie 192: 834-835 abstr. 2.2, No. 11, Nov 2016. Available from: URL: http://doi.org/10.1007/s00066-016-1051-3 [abstract] - Switzerland

Copyright information

© Springer International Publishing Switzerland 2017

Personalised recommendations